Clinical consequences of the presence of anti-RNA Pol III antibodies in systemic sclerosis
| Autor: | Magdalena Dryglewska, Ewa Wielosz, Maria Majdan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
systemic sclerosis Scleroderma Renal Crisis Dermatology Malignancy Gastroenterology RNA polymerase III Serology 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Internal medicine Immunology and Allergy Medicine In patient skin and connective tissue diseases Kidney Original Paper biology integumentary system business.industry Incidence (epidemiology) medicine.disease RC31-1245 medicine.anatomical_structure RL1-803 malignancies biology.protein anti-RNA Pol III antibodies Antibody business |
| Zdroj: | Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii Advances in Dermatology and Allergology, Vol 37, Iss 6, Pp 909-914 (2021) |
| ISSN: | 2299-0046 1642-395X |
| Popis: | Introduction Anti-RNA polymerase III (a-RNA Pol III) antibodies are marker antibodies in patients with systemic sclerosis (SSc). Aim To assess the prevalence of a-RNA Pol III in patients with SSc and to identify the differences in the disease picture in SSc patients with and without a-RNA Pol III antibodies. Material and methods The study was performed in 126 SSc patients. The subtype of SSc, incidence of internal organ involvement, malignancy, death and serological profiles were determined in the entire group. The study groups were studied according to the presence of antibodies by applying the commercial test - EUROLINE SSc Profile. Due to the presence of a-RNA Pol III, patients were divided into two groups: the a-RNA Pol III (+) SSc group of 19 patients and the a-RNA Pol III (-) SSc group of 107 patients. Results A-RNA Pol III were present in 19/126 patients with SSc (15%), 13/19 (68.4%) patients had no other SSc marker antibodies. A-RNA Pol III were more common in patients with diffuse cutaneous SSc (p = 0.049). We showed a significant positive association between a-RNA Pol III and occurrence of malignancy (p = 0.007), scleroderma renal crisis (p = 0.001) and decreased DLCO (p = 0.007). Conclusions Anti-a-RNA Pol III antibodies are common in patients with SSc, particularly with a diffuse subtype. In more than 50% of patients with a-RNA Pol III antibodies, they may be present as the sole marker of antibodies. In SSc, a-RNA Pol III antibodies are frequently associated with malignancy occurrence, kidney and lung involvement. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|